CorMedix (CRMD) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates
August 5, 2016 8:05 AM EDTBEDMINSTER, NJ -- (Marketwired) -- 08/05/16 -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2016 and highlighted recent business updates. The Company will host a conference call today at 9:00 a.m. Eastern Time.
Key Business and Financial Updates:
Neutrolin Phase 3 LOCK-IT 100 study in hemodialysis patients: Continue to enroll patients and engage clinical sites; overall program remains on track. Anticipated... More
